Metolazone NDC 71610-285

NDC codes

FDA NDC Directory

Product NDC (as listed)71610-285Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71610-0285Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71610-285-09	71610028509	9000 TABLET in 1 BOTTLE (71610-285-09)Marketed from May 31, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metolazone
Generic name (nonproprietary): metolazone
Active ingredients: Metolazone — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aphena Pharma Solutions - Tennessee, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076732
Marketing start: Dec 19, 2003
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis (Physiologic effect)
Identifiers: Product ID 71610-285_875c85ff-ca13-41b1-bc4e-ca871c3d2cd1SPL ID 875c85ff-ca13-41b1-bc4e-ca871c3d2cd1SPL set ID 71f86ee1-9e43-482b-9ad8-ec5d5576f360RxCUI 197979, 311671UNII TZ7V40X7VX
Pharmacologic class: Thiazide-like Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471610028509 followed by a unit qualifier and the quantity

Package 71610-0285-09. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 3, 2019.

Indications (excerpt from the label)

INDICATIONS AND USAGE Metolazone is indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its s…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076732

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076732
Product	Strength	Form · route	Labeler	Product NDC
Metolazone	Metolazone 2.5 mg/1	TabletOral	Bryant Ranch Prepack	63629-8722
Metolazone	Metolazone 2.5 mg/1	TabletOral	Sandoz Inc	0185-5050
Metolazone	Metolazone 2.5 mg/1	TabletOral	Bryant Ranch Prepack	72162-1056